secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-027935
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta
--------------------------------------------------------------------------------

- Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.
- Cash, equivalents and marketable securities $286.7M as of June 30, expected to fund ops into 2H 2025.
- Exclusive license for CFT8919 (EGFR L858R degrader) with Betta Pharma in Greater China: $10M upfront, $25M equity investment, up to $357M milestones plus royalties.
- U.S. IND cleared for CFT8919; Phase 1/2 trials for CFT7455, CFT8634, CFT1946 ongoing; Phase 1 dose escalation data expected 2H 2023.
- Appointed Len Reyno as CMO and Mary Christian as SVP Regulatory in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/0001628280-23-027935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/cccc-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer